407 related articles for article (PubMed ID: 32013913)
21. Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?
Romano MR; Gibran SK; Marticorena J; Wong D; Heimann H
Eur J Ophthalmol; 2009; 19(4):618-21. PubMed ID: 19551678
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal bevacizumab at the end of diabetic vitrectomy for prevention of postoperative vitreous hemorrhage: a comparative study.
Jirawison C; Ittipunkul N
J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S136-42. PubMed ID: 22696866
[TBL] [Abstract][Full Text] [Related]
23. A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy.
Yang X; Xu J; Wang R; Mei Y; Lei H; Liu J; Zhang T; Zhao H
J Ophthalmol; 2016; 2016():2473234. PubMed ID: 27034822
[TBL] [Abstract][Full Text] [Related]
24. Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial.
Aleman I; Castillo Velazquez J; Rush SW; Rush RB
Br J Ophthalmol; 2019 Dec; 103(12):1740-1746. PubMed ID: 30705040
[TBL] [Abstract][Full Text] [Related]
25. The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage.
Berk Ergun S; Toklu Y; Cakmak HB; Raza S; Simsek S
Semin Ophthalmol; 2015 May; 30(3):177-80. PubMed ID: 24409948
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy.
Yeh PT; Yang CH; Yang CM
Acta Ophthalmol; 2011 Nov; 89(7):634-40. PubMed ID: 20064118
[TBL] [Abstract][Full Text] [Related]
27. INTERNAL LIMITING MEMBRANE PEELING DURING VITRECTOMY FOR DIABETIC VITREOUS HEMORRHAGE: A Randomized Clinical Trial.
Rush RB; Del Valle Penella A; Reinauer RM; Rush SW; Bastar PG
Retina; 2021 May; 41(5):1118-1126. PubMed ID: 32910084
[TBL] [Abstract][Full Text] [Related]
28. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
29. Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment.
Yeung L; Liu L; Wu WC; Kuo YH; Chao AN; Chen KJ; Yang KJ; Chen TL; Lai CC
Acta Ophthalmol; 2010 Sep; 88(6):635-40. PubMed ID: 19432872
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy.
Modarres M; Nazari H; Falavarjani KG; Naseripour M; Hashemi M; Parvaresh MM
Eur J Ophthalmol; 2009; 19(5):848-52. PubMed ID: 19787608
[TBL] [Abstract][Full Text] [Related]
31. Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage.
Cheema RA; Mushtaq J; Al-Khars W; Al-Askar E; Cheema MA
Retina; 2010; 30(10):1646-50. PubMed ID: 20634777
[TBL] [Abstract][Full Text] [Related]
32. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
Diabetic Retinopathy Clinical Research Network*
JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
[TBL] [Abstract][Full Text] [Related]
33. INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY.
Su L; Ren X; Wei H; Zhao L; Zhang X; Liu J; Su C; Tan L; Li X
Retina; 2016 May; 36(5):938-43. PubMed ID: 26630313
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy.
Jonas JB; Söfker A; Degenring R
Eur J Ophthalmol; 2003 Jun; 13(5):468-73. PubMed ID: 12841570
[TBL] [Abstract][Full Text] [Related]
35. RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
Manabe A; Shimada H; Hattori T; Nakashizuka H; Yuzawa M
Retina; 2015 Sep; 35(9):1800-7. PubMed ID: 25932549
[TBL] [Abstract][Full Text] [Related]
36. One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.
Zhou Q; Guo C; You A; Wang D; Wang W; Zhang X
Mol Vis; 2019; 25():636-644. PubMed ID: 31700228
[TBL] [Abstract][Full Text] [Related]
37. Effect of Intravitreal Conbercept Injection on Complications of Pars Plana Vitrectomy in Patients with Proliferative Diabetic Retinopathy.
Ding Y; Su N; Luan J; Ni Y; Sun Z
J Pers Med; 2023 Mar; 13(4):. PubMed ID: 37108958
[TBL] [Abstract][Full Text] [Related]
38. A Systematic Review and Meta-Analysis of Clinical Outcomes of Small Gauge Vitrectomy with or without Intravitreal Anti-Vascular Endothelial Growth Factor Agents Pretreatment for Proliferative Diabetic Retinopathy.
Pei M; Zhao X; Wan G
Ophthalmic Res; 2023; 66(1):777-790. PubMed ID: 36972566
[TBL] [Abstract][Full Text] [Related]
39. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema.
Yamamoto T; Hitani K; Tsukahara I; Yamamoto S; Kawasaki R; Yamashita H; Takeuchi S
Am J Ophthalmol; 2003 Jan; 135(1):14-9. PubMed ID: 12504691
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab for postoperative recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy.
Ferenchak K; Duval R; Cohen JA; MacCumber MW
Retina; 2014 Jun; 34(6):1177-81. PubMed ID: 24457977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
